ARAF recurrent mutation causes central conducting lymphatic anomaly treatable with a MEK inhibitor. - Li D; March ME; Gutierrez-Uzquiza A; Kao C; Seiler C; Pinto E; Matsuoka LS; Battig MR; Bhoj EJ; Wenger TL; Tian L; Robinson N; et al. (Nature medicine, 2019)